On Monday, Travere Therapeutics Inc (NASDAQ: TVTX) opened higher 3.02% from the last session, before settling in for the closing price of $17.57. Price fluctuations for TVTX have ranged from $5.12 to $19.25 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 3.07%. Company’s average yearly earnings per share was noted -162.07% at the time writing. With a float of $76.87 million, this company’s outstanding shares have now reached $78.05 million.
The extent of productivity of a business whose workforce counts for 380 workers is very important to gauge. In terms of profitability, gross margin is 78.77%, operating margin of -169.03%, and the pretax margin is -171.4%.
Travere Therapeutics Inc (TVTX) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Travere Therapeutics Inc is 1.51%, while institutional ownership is 114.00%. The most recent insider transaction that took place on Oct 04 ’24, was worth 589,101. In this transaction Director of this company sold 40,000 shares at a rate of $14.73, taking the stock ownership to the 51,000 shares. Before that another transaction happened on Oct 04 ’24, when Company’s Officer proposed sale 40,000 for $13.65, making the entire transaction worth $546,000.
Travere Therapeutics Inc (TVTX) Latest Financial update
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -1.18 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -1.27) by 0.09. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.49 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -162.07% per share during the next fiscal year.
Travere Therapeutics Inc (NASDAQ: TVTX) Trading Performance Indicators
Check out the current performance indicators for Travere Therapeutics Inc (TVTX). In the past quarter, the stock posted a quick ratio of 1.68. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.97.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.56, a number that is poised to hit -0.63 in the next quarter and is forecasted to reach -1.16 in one year’s time.
Technical Analysis of Travere Therapeutics Inc (TVTX)
The latest stats from [Travere Therapeutics Inc, TVTX] show that its last 5-days average volume of 1.69 million was superior to 1.4 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 43.15%. Additionally, its Average True Range was 1.11.
During the past 100 days, Travere Therapeutics Inc’s (TVTX) raw stochastic average was set at 90.76%, which indicates a significant increase from 53.63% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 31.67% in the past 14 days, which was lower than the 62.56% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.70, while its 200-day Moving Average is $9.55. Now, the first resistance to watch is $18.77. This is followed by the second major resistance level at $19.44. The third major resistance level sits at $20.38. If the price goes on to break the first support level at $17.16, it is likely to go to the next support level at $16.22. The third support level lies at $15.55 if the price breaches the second support level.
Travere Therapeutics Inc (NASDAQ: TVTX) Key Stats
There are currently 76,491K shares outstanding in the company with a market cap of 1.42 billion. Presently, the company’s annual sales total 145,240 K according to its annual income of -111,400 K. Last quarter, the company’s sales amounted to 54,120 K and its income totaled -70,410 K.
